Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label ACH-0144471 extension study in PNH after ACH471-100
2017-000665-79Phase 2Unknown
- Sponsor
- Achillion Pharmaceuticals
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Achillion Pharmaceuticals. Primary endpoints: Efficacy based on hemolysis and hematologic parameters and Red blood cell transfusion burden. Status: unknown.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2017-000665-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000665-79.